达雷妥尤单抗联合地塞米松治疗三重难治性骨髓瘤安全有效:IFM 2014-04(Etoile du Nord)试验最终结果
Single agent daratumumab has shown clinical activity in relapsed, refractory multiple myeloma (RRMM). The Intergroupe Francophone du Myélome 2014-04 trial was designed to further investigate daratumumab in combination with dexamethasone in triple RRMM patients.…
要点
- 达雷妥尤单抗联合地塞米松治疗三重难治性骨髓瘤总缓解率 33%,临床获益率 48%。
- 输注相关反应发生率 37%,均可管理,未导致减量或永久停药。
核心结论
- 达雷妥尤单抗联合地塞米松治疗三重难治性复发难治多发性骨髓瘤患者可获得有意义的长期获益,且安全性可接受。
主要发现
- 总缓解率为 33%(n=19),临床获益率为 48%(n=27)。
- 中位至缓解时间为 4 周。
临床怎么用
- 对于三重难治性复发难治多发性骨髓瘤患者,达雷妥尤单抗联合每周地塞米松可作为治疗选择,需监测并管理输注相关反应。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Single agent daratumumab has shown clinical activity in relapsed, refractory multiple myeloma (RRMM). The Intergroupe Francophone du Myélome 2014-04 trial was designed to further investigate daratumumab in combination with dexamethasone in triple RRMM patients. Patients received daratumumab infusions in combination with weekly dexamethasone until disease progression or unacceptable toxicity. Fifty-seven patients were included in the trial and evaluable for response. The overall response rate and the clinical benefit rate were 33% (n = 19) and 48% (n = 27), respectively. Five (8·8%) patients achieved a very good partial response or better. The median time to response was 4 weeks. For responding patients, the median progression-free survival was 6·6 months, compared to 3·7 months (3·0-5·5) for those with a minimal or stable disease. The median overall survival (OS) for all patients was 16·7 months (11·2-24·0). For responding patients, the median OS was 23·23 months, whereas that of patients with progressive disease was 2·97 months. The incidence of infusion-related reactions was 37%; all cases were manageable and did not lead to dose reduction or permanent treatment discontinuation. These data demonstrate that treatment with daratumumab and dexamethasone results in a meaningful long-term benefit with an acceptable safety profile for patients with triple RRMM.
引用
- Boyle EM, Leleu X, Petillon MO, et al. Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial. Br J Haematol. 2019. PMID: 31218679. doi:10.1111/bjh.16059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。